The Multiple Sclerosis Association of America (MSAA) is pleased to introduce our new logo and redesigned website homepage! As we enter our 50th year of dedicated service to the MS community, we are proud to share this important announcement about our new brand identity. While we are excited about our new look, please be assured […]

The Multiple Sclerosis Association of America (MSAA) is proud to announce the new Chairperson of the Healthcare Advisory Council for the organization. Dr. Carrie Hersh, a multiple sclerosis specialist at the Cleveland Clinic Lou Ruvo Center for Brain Health – Las Vegas, has assumed the position. Dr. Hersh joined the faculty at the Cleveland Clinic […]

Reviewed by MSAA Chief Medical Officer Barry A. Hendin, MD On December 5, 2019, the United States Food and Drug Administration (FDA) announced that they had approved the applications from three separate pharmaceutical companies for the first generic versions of Gilenya® (fingolimod) capsules for the treatment of relapsing forms of multiple sclerosis (MS) in adult […]

Reviewed by MSAA Chief Medical Officer Barry A. Hendin, MD In this Article Experimental and Approved Disease-Modifying Therapies Treatment Strategies and Trends Other Interventions Disease Course and Risk Factors For More Information References ECTRIMS Annual Meeting Highlights This edition of MSAA’s “What’s New in MS Research” provides highlights from this year’s European Committee for Treatment […]

Reviewed by MSAA Chief Medical Officer Barry A. Hendin, MD On October 30, 2019, Biogen Inc. and Alkermes plc announced the United States Food and Drug Administration (FDA) approval of Vumerity™ (diroximel fumarate) oral capsules to treat adults with relapsing forms of multiple sclerosis (MS). This approval includes the treatment of clinically isolated syndrome (CIS), […]

The Multiple Sclerosis Association of America (MSAA), in partnership with Novartis Pharmaceuticals Corporation and Emmy Award-winning television personality and multiple sclerosis (MS) advocate Montel Williams, announced today the launch of My MS Second Act. The educational program aims to improve awareness about MS disease progression and secondary-progressive MS (SPMS) and underscores the need for early […]

The Multiple Sclerosis Association of America (MSAA) is proud to announce a partnership with eSSENTIAL Accessibility, a comprehensive digital accessibility platform to assist in continuing MSAA’s commitment in providing informative and accessible resources to members of the multiple sclerosis (MS) community. Many individuals have difficulty typing, moving a mouse, or reading due to a variety […]

If you have any doubts about the breadth and depth of ongoing research into the causes, nature, and treatment of multiple sclerosis (MS), the 12 items that follow should entirely allay those concerns. This latest edition of “What’s New in MS Research” reports on findings from the depths of the seas to the aisles of your local supermarket, and then to laboratories, hospitals, and MS clinics.